Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251520 · ClinicalTrials.gov registry record · NA
The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT04251520: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT04251520 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251520, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.
Primary Outcome
Measure using the self-reported Edmonton Symptom Assessment scale where a lower score indicates good symptom control and higher score indicates poor symptom control
Interventions
- DIAGNOSTIC_TEST Pharmacogenomics testing
- OTHER Pharmacist review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-01-12 |
| Phase | NA |
Why NCT04251520 stopped before completion
NCT04251520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenomics testing is the first listed.
NCT04251520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04251520 about?
NCT04251520 is a clinical study titled "The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients". Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.
What is the current status of trial NCT04251520?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2021-04-15. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04251520?
The interventions under investigation include: Pharmacogenomics testing (DIAGNOSTIC_TEST), Pharmacist review (OTHER).
Who is sponsoring clinical trial NCT04251520?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04251520's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI